Novartis Follows Eli Lilly with $1.4 Billion Gene Editing Pact
Precision BioSciences is developing gene editing tools with several potential advantages over CRISPR.
Novartis Follows Eli Lilly with $1.4 Billion Gene Editing Pact
Precision BioSciences is developing gene editing tools with several potential advantages over CRISPR.